Interactions between cardiology and oncology drugs in precision cardio-oncology.

Recent advances in treatment have transformed the management of cancer. Despite these advances, cardiovascular disease remains a leading cause of death in cancer survivors. Cardio-oncology has recently evolved as a subspecialty to prevent, diagnose, and manage cardiovascular side effects of antineoplastic therapy. An emphasis on optimal management of comorbidities and close attention to drug interactions are important in cardio-oncologic care. With interdisciplinary collaboration among oncologists, cardiologists, and pharmacists, there is potential to prevent and reduce drug-related toxicities of treatments. The cytochrome P450 (CYP450) family of enzymes and the P-glycoprotein (P-g) transporter play a crucial role in drug metabolism and drug resistance. Here we discuss the role of CYP450 and P-g in drug interactions in the field of cardio-oncology, provide an overview of the cardiotoxicity of a spectrum of cancer agents, highlight the role of precision medicine, and encourage a multidisciplinary treatment approach for patients with cancer.

Biogeochemical oxidation of calcium sulfite hemihydrate to gypsum in flue gas desulfurization byproduct using sulfur-oxidizing bacteria.

Flue gas desulfurization (FGD) is a well-established air treatment technology for coal and oil combustion gases that commonly uses lime or pulverized limestone aqueous slurries to precipitate sulfur dioxide (SO2) as crystalline calcium salts. Under forced oxidation (excess oxygen) conditions, FGD byproduct contains almost entirely (>92%) gypsum (CaSO4·2H2O), a useful and marketable commodity. In contrast, FGD byproduct formed in oxygen deficient oxidation systems contains a high percentage of hannebachite (CaSO3·0.5H2O) to yield a material with no commercial value, poor dewatering characteristics, and that is typically disposed in landfills. Hannebachite in FGD byproduct can be chemically converted to gypsum; however, the conditions that support rapid formation of gypsum require large quantities of acids or oxidizers. This work describes a novel, patent pending application of microbial physiology where a natural consortium of sulfur-oxidizing bacteria (SOB) was used to convert hannebachite-enriched FGD byproduct into a commercially valuable, gypsum-enriched product (US Patent Assignment 503373611). To optimize the conversion of hannebachite into gypsum, physiological studies on the SOB were performed to define their growth characteristics. The SOB were found to be aerobic, mesophilic, neutrophilic, and dependent on a ready supply of ammonia. They were capable of converting hannebachite to gypsum at a rate of approximately five percent per day when the culture was applied to a 20 percent FGD byproduct slurry and SOB growth medium. 16S rDNA sequencing revealed that the SOB consortium contained a variety of different bacterial genera including both SOB and sulfate-reducing bacteria. Halothiobacillus, Thiovirga and Thiomonas were the dominant sulfur-oxidizing genera.